Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-31T14:47:56.009Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Trial of Mebanazine (‘Actomol’) in Depression

Published online by Cambridge University Press:  29 January 2018

J. C. Barker ,
I. A. Jan  and
M. David Enoch
J. C. Barker
Affiliation:
Shelton Hospital, Shrewsbury
I. A. Jan
Affiliation:
Shelton Hospital, Shrewsbury
M. David Enoch
Affiliation:
Shelton Hospital, Shrewsbury
Get access Rights & Permissions [Opens in a new window]

Extract

Mebanazine (‘Actomol’) introduced in 1960 for the treatment of depression is a monoamine-oxidase inhibitor hydrazine derivative having the following structural formula:

Type
Research Article
Information
The British Journal of Psychiatry , Volume 111 , Issue 480 , November 1965 , pp. 1095 - 1100
Copyright
Copyright © Royal College of Psychiatrists, 1965 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cooper, A. J., and Keddie, K. M. G. (1964). Lancet, 1, 1133.Google Scholar
Enoch, M. D., and Barker, J. C. (1964). Lancet, 1, 44.Google Scholar
Herridge, C. F. (1964). Lancet, 2, 48.Google Scholar
Horne, P. M., and Forrest, A. D. (1962). Scot. med. J., 7, 224.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.